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Visual short-term memory binding 
deficit with age-related hearing loss 
in cognitively normal older adults
David G. Loughrey1,2, Mario A. parra3,4 & Brian A. Lawlor1,2,5,6
Age-related hearing loss (ARHL) has been posited as a possible modifiable risk factor for neurocognitive 
impairment and dementia. Measures sensitive to early neurocognitive changes associated with 
ARHL would help to elucidate the mechanisms underpinning this relationship. We hypothesized that 
ARHL might be associated with decline in visual short-term memory binding (VSTMB), a potential 
biomarker for preclinical dementia due to Alzheimer’s disease (AD). We examined differences in 
accuracy between older adults with hearing loss and a control group on the VSTMB task from a single 
feature (shapes) condition to a feature binding (shapes-colors) condition. Hearing loss was associated 
with a weaker capacity to process bound features which appeared to be accounted for by a weaker 
sensitivity for change detection (A’). Our findings give insight into the neural mechanisms underpinning 
neurocognitive decline with ARHL and its temporal sequence.
Age-related hearing loss (ARHL), the third most common chronic health condition among older adults1, has 
been recognized as a potential risk factor for dementia1–3. Effective management of ARHL could potentially have 
the biggest public health impact for any modifiable dementia risk factor3. However, it is not clear how ARHL is 
associated with dementia and there are several different hypotheses2. Measures sensitive to early neurocognitive 
changes associated with ARHL that identify risk of neurocognitive impairment would help to elucidate the mech-
anisms underpinning this relationship and would be valuable diagnostically and in clinical trials.
A challenge in developing accurate biomarkers of dementia risk is that executive neurocognitive networks 
may provide compensatory mechanisms which mask or delay clinical expression of neuropathological-related 
lesions4. Epidemiological and experimental evidence suggests that such networks are relatively maintained with 
ARHL because they are increasingly recruited for auditory processing to the detriment of lower-level processes 
such as encoding in working memory which are disrupted5. This may lead to an underestimation of cognitive 
decline following ARHL in its earlier stages and of the effectiveness of intervention when relying on traditional 
neuropsychological instruments to assess outcomes6.
Visual Short-Term Memory Binding (VSTMB) is a function responsible for binding features of an object 
temporarily in working memory7 and is sensitive to Alzheimer’s disease (AD) along its continuum beginning 
with the pre-hippocampal stages8,9. Encoding of bound visual features occurs automatically without reliance on 
executive resources10 but can be disrupted by increased cognitive load11 including that due to processing verbal 
stimuli12 as occurs in ARHL. Hence, the VSTMB test may unveil the neurocognitive impact of ARHL and more 
reliably identify risk of dementia due to AD during preclinical stages. In this study, we hypothesized that ARHL 
is associated with weaker VSTMB in cognitively normal adults.
Methods
Participants. Volunteers in this study were community-dwelling adults over the age of 50 recruited from the 
general population through community organizations and audiometric clinics for a study on ARHL and cogni-
tion. There were 25 participants in the hearing loss group (HLG) and 18 in the control group (CG). Volunteers 
were excluded from the study if they had a history of brain injury, epilepsy, stroke, neurological conditions, a 
history of drug/alcohol abuse, hospitalization for mental/emotional problems in the previous five years, if they 
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were taking certain medications for a psychiatric condition, if they had possible cognitive impairment (based 
on a global cognitive z-score of <−1.5 SD on the neuropsychological assessment tests) or if they had a con-
genital/pre-lingual hearing loss or loss due to injury or disease. The Faculty of Health Sciences Research Ethics 
Committee of Trinity College Dublin approved all study protocols. The study was conducted in accordance with 
the 1964 Declaration of Helsinki, and its later amendments. Written informed consent was obtained from all 
participants. Testing with the VSTMB task took place between October 2016 and January 2017.
Background assessment. Demographic data collected included age, sex, and education (both years and 
highest attainment). Self-rated measures were included of physical and mental health, alcohol consumption 
and smoking. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI)S1; pre-morbid IQ using 
the National Adult Reading Test (NART)S2; frailty with the Survey of Health, Ageing and Retirement in Europe 
(SHARE) Frailty InstrumentS3; depression with the 10 item Center for Epidemiologic Studies Depression Scale 
(CESD-10)S4; anxiety using the Hospital Anxiety and Depression Scale-Anxiety subscale (HADS-A)S5; apathy 
with the Apathy Evaluation Scale – Self-rated (AES-S)S6; social network with the Lubben Social Network Scale 
(LSNS)S7; loneliness with the 6-item De Jong Gierveld Loneliness Scale (DJGLS)S8; boredom proneness using a 
self-report question with a four-point scaleS9; perceived stress with the Perceived Stress Scale-4 item (PSS-4)S10. The 
Hearing Handicap Inventory for the Elderly Screening Version (HHIE-S) assessed self-reported hearing lossS11.
Audiometric assessment. Pure-tone audiometry was used to assess peripheral ear function. The assess-
ment was conducted by audiologists and followed the standards of the British Society of Audiology and of 
the American National Standards Institute. Participants’ ears were checked by otoscope. Pure-tone air conduc-
tion decibel thresholds were obtained in each ear at frequencies 0.5, 1, 2, 3, 4, 6, and 8 kilohertz with calibrated 
audiometers (Grayson Sadler GSI 61 or Interacoustics Callisto) and TDH 39 supra-aural earphones (Telephonics, 
Huntington, New York). The World Health Organization (WHO) criteria for hearing loss were used: pure-tone 
average (PTA) ≥ 26 dB for 0.5, 1, 2 & 4 kHz in the better ear13. Participants meeting these criteria were allocated to 
HLG and those below this threshold were allocated to CG. We also calculated the PTA of these frequencies for the 
worse ear. The PTA for low (0.25, 0.5 & 1 kHz) and high frequencies (3, 4, & 6 kHz) for both ears were included to 
provide an estimate of low and high frequency loss.
Neuropsychological assessment. We conducted a neuropsychological assessment of the main cognitive 
domains. General cognitive function was assessed using the Montreal Cognitive Assessment (MoCA)S12 and a 
composite z-score was calculated from tests of the following domains: episodic memory was assessed using the 
Free and Cued Selective Reminding Test (FCSRT)S13 with immediate and delayed recall (after 30 minutes) subsets 
and Wechsler Memory Scale-III (WMS-III) spatial span forward subsetS14; executive function was assessed using 
the Visual Reasoning subtest of the Cambridge Mental Disorders of the Elderly Examination (CAMDEX) bat-
teryS15, the Sustained Attention to Response task (SART)S16, the phonological fluency test from the MoCAe12 
and the WMS-III spatial span backward subsetS14; processing speed was assessed using a computer-based 
choice-reaction time test (CRT) which included motor and cognitive componentsS17 and mean response time 
(RT) from the SARTS16; language was assessed using the Boston Naming Test 60-item versionS18 and the semantic 
(animals) fluencyS19 and visuospatial ability was assessed using the Medical College of Georgia (MCG) Complex 
Figure test (copy only)S20. None of the tests used auditory stimuli except the MoCA (we used scores both includ-
ing and excluding audiological items)S21.
VSTMB test. Using a computer, participants were administered a screening test (to ensure capacity to form 
bindings in perception) and the VSTMB test which was the same as that used by Parra et al. (2010)9. Participants 
were asked to remember two study visual arrays (2000 ms) and after a brief pause (900 ms) to detect if a change 
has occurred when visually prompted with a test array (Fig. 1). The first condition consisted of two shapes-only 
arrays. The second condition consisted of two colored shapes arrays. In both conditions, participants were 
instructed to state verbally whether or not the stimulus in the test display was the ‘same’ (as) or ‘different’ (from) 
the stimulus in the study display. Participants were allowed to respond in their own time. At the beginning of each 
trial, a fixation screen appeared for 250 ms. Changes in the test arrays consisted of new features replacing studied 
features (shape-only) or features swapping across items (shape-color binding). For the first condition, the two 
arrays were randomly selected from a set of eight six-sided random polygons shapes. For the second condition, 
the two arrays were selected from the same selection of shapes and from a set of eight colors. Both the shapes and 
binding conditions consisted of 15 practice trials followed by 32 test trials. Of these 32 trials, 16 were ‘same trials’ 
and 16 were ‘different trials.’ Stimuli were presented at 1° of visual angle and fell within an area of 10°. Participants 
were instructed to ignore the location of the stimulus on the screen which varied randomly across trials and 
between study and test displays. The test took approximately 16 minutes to complete.
Statistical analysis. We compared background and neuropsychological data, using the unpaired t-test or 
the χ2 test. Normality was examined using the Kolmogorov-Smirnov test and by visual inspection of the Q-Q 
plots and the data distribution in the histograms. Non-normal data were either transformed or analyzed using 
non-parametric tests, as appropriate. All statistical analyses were conducted using the Statistical Package for 
Social Sciences version 22 (SPSS Inc., Chicago, IL, U.S.A.).
We used a linear mixed model to conduct the primary analysis to assess difference between groups across 
VSTMB conditions (shapes to binding). As fixed effects in the model, we entered condition, group and a con-
dition by group interaction term. Subject was entered as a random effect. Age, sex and years of education were 
entered as covariates. Residual plots were inspected for deviations from homoscedasticity or normality. We con-
structed another model with the slope added as a random factor. Models were fitted and compared based on the 
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−2 Restricted Log Likelihood and Akaike’s Information Criterion. The first model was deemed the better fit. We 
selected a diagonal structure as the covariance structure for the error terms based on the above criteria.
As a secondary analysis, we assessed the differences between groups on all VSTMB outcomes using ANCOVA 
with the same covariates. We conducted an additional analysis assessing sensitivity for change detection9 follow-
ing Signal Detection Theory measures14. A’ was selected as the sensitivity measure15 and was calculated accord-
ing to the formulas provided by Xu16 which do not have indeterminacy when a participant does not make false 
alarms. Poor performance accounted for by low sensitivity would suggest difficulties in keeping the signal sepa-
rate from the noise in working memory9.
Using Pearson’s r or Spearman’s correlation coefficient, we explored associations between shapes and bind-
ing accuracy with hearing loss (WHO PTA for entire sample) along with age and other variables recognized as 
potential modifiable dementia risk factors (depression, level of education, physical inactivity, smoking, and social 
engagement)3. We explored associations between shapes and binding accuracy with outcomes on several tests 
recommended for AD assessment (FCSRT delayed free recall, phonemic/semantic fluency, BNT and MoCA)4 
across groups17. We made adjustments for false discovery rates. We also compared VSTMB high and low HLG 
performers and the CG on background and neuropsychological data.
Results
Group characteristics. Groups were well matched on background factors (Table 1). A significant difference 
existed between groups on all audiological outcomes (P < 0.001). Seventeen (68%) of the participants in the HLG 
and none in the CG wore hearing aids. Thirteen (52%) participants in the HLG and thirteen (72%) in the CG 
reported having previously experienced tinnitus. No participants reported difficulty with vision. All participants 
passed the perceptual binding screening assessment. No significant difference was observed between groups on 
any traditional neuropsychological test except for visuospatial ability where the HLG performed more poorly 
(mean [SD], 24.22 [4.38] vs 27.06 [4.5]; P = 0.045) (Table 2).
VSTMB results. Prior to adding the interaction term, there was no significant effect for any variable except 
condition (Table 3). When the interaction term was added to the model, it was the only significant variable, 
with HLG demonstrating a greater drop in accuracy from the shapes to the binding condition (β = −0.064, 95% 
CI = −0.125 to −0.003; P = 0.04).
Results of the secondary (ANCOVA) analyses for each VSTMB outcome (Table 3) showed no significant 
difference between groups on the shapes-only condition outcomes. For the binding condition, we found no sig-
nificant difference in reaction time. The HLG demonstrated poorer performance compared to CG on binding 
accuracy (0.86 [0.11] vs 0.93 [0.06]; P = 0.03). We found no significant difference for the sensitivity measure (A’) 
on shapes-only condition; however, a lower sensitivity for the HLG approached significance on the binding con-
dition (0.8 [0.23] vs 0.92 [0.08]; P = 0.06).
VSTMB associations with dementia risk factors and assessment tools. Compared to age and 
other, modifiable, dementia risk factors only hearing loss was associated with binding accuracy whereas only 
social engagement was significantly associated with shapes accuracy. (Supplementary Table S1). When compared 
with other AD assessment tools, only phonemic fluency was significantly correlated with binding accuracy in the 
HLG (Supplementary Table S2). These findings remained after removal of low performers from the CG. None 
of the above associations remained significant after adjustment for false discovery rate17. We included correla-
tions between shapes/binding accuracy and all background and neuropsychological variables in Supplementary 
Tables S3 and S4.
Figure 1. The two conditions (shapes and shapes-colors binding) of the Visual Short-Term Memory Binding 
Task.
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High vs low VSTMB performers. The total sample mean (0.89) was used as the cut-off point in binding 
accuracy in the HLG which gave 11 HLG-high and 14 HLG-low performers (Supplementary Table S5 and S6). 
Outcomes for the three groups on background measures were the same (P > 0.10) except NART scores which 
trended toward significance (HLG-low = 110.88 [6.25], HLG-high = 115.39 [6.48], CG = 115.17 [5.38]; P = 0.09). 
For neuropsychological tests, outcomes were the same across groups (P > 0.10) with the exceptions of phone-
mic fluency (HLG-low = 13.29 [4.2], HLG-high = 17.27 [4.74], CG = 14.22 [4.17]; P = 0.07) and the MCG com-
plex figure copy task (HLG-low = 23.5 [4.26], HLG-high = 25.14 [4.57], CG = 27.06 [4.5]; P = 0.09) which also 
trended toward significance. These findings remained unchanged with removal of low performers from the CG 
(N = 4). When only HLG-high performers and HLG-low performers were compared, there were no differences 
(P > 0.10) with the exceptions that the HLG-low had greater low-frequency hearing loss (both P < 0.10) and 
poorer NART scores (P = 0.09) and phonemic fluency (P = 0.04).
Discussion
Compared to controls, the HLG showed poorer capacity to process bound features in visual short-term memory. 
We found no difference in accuracy between groups on the shapes-only condition. The two groups were other-
wise matched for background characteristics and neuropsychological performance (with the exception of the 
MCG complex figure copy task). All participants passed the perceptual binding screening assessment. Therefore, 
decline in processing bound features was more likely due to a weaker capacity to maintain a strong signal-to-noise 
HLG M (SD) CG M (SD) p
Demographic
N 25 18 —
Age 72.56 (5.79) 69.11 (6.63) 0.08
Sex (female/male) 14/11 14/4 0.25
Education (years) 13.58 (3.62) 14.44 (3.09) 0.42
Education (level) 2.8 (0.76) 2.94 (0.73) 0.45
Audiological
WHO better ear PTA 49.9 (17.23) 13.61 (6.61) <0.001
WHO worse ear PTA 63.2 (25.76) 19.17 (8.73) <0.001
Low freq. better ear PTA 54.64 (13.29) 12.64 (9.38) <0.001
Low freq. worse ear PTA 68.93 (18.62) 19.89 (17.47) <0.001
High freq. better ear PTA 75.6 (14.8) 34.02 (16.56) <0.001
High freq. worse ear PTA 90.12 (21.41) 42.87 (19.36) <0.001
Self-rated hearing (HHIE-S) 20.0 (8.43) 4.44 (6.49) <0.001
Health and psychosocial function
Self-rated physical health 3.52 (1.01) 3.83 (1.04) 0.34
Self-rated mental health 3.96 (0.84) 3.94 (1.11) 0.89
Physical inactivity level 2.04 (1.02) 2 (0.77) 0.97
Alcohol consumption (yes/no) 19/6 14/4 >0.99
Alcohol units (per wk) 8.49 (7.11) 12.64 (11.74) 0.26
Smoker current (yes/no) 1/24 0/18 >0.99
Smoker former (yes/no) 10/15 7/11 >0.99
Sleep quality (PSQI) 5.24 (3.02) 4.78 (2.53) 0.66
Pre-morbid IQ (NART) 112.87 (6.62) 115.17 (5.38) 0.23
Self-rated memory 3.32 (0.85) 3.56 (0.86) 0.35
Frailty (SHARE score) 0.26 (0.87) 0.21 (1.07) 0.69
Depression (CESD-10) 4.24 (3.02) 4.83 (4.46) 0.95
Anxiety (HADS-A) 3.48 (2.58) 3.83 (3.5) 0.96
Apathy (AES-S) 26.92 (4.65) 27.83 (7.21) 0.9
Social network (LSNS) 20.56 (5.55) 19.5 (6.17) 0.9
Loneliness (DJGLS) 0.32 (0.69) 0.83 (1.62) 0.39
Boredom proneness (Conroy) 1.36 (0.57) 1.61 (0.7) 0.21
Perceived stress (PSS-4) 3.08 (2.18) 2.33 (2.72) 0.14
Table 1. Background data for the two groups of participants. Means (M) and standard deviations (SD) for the 
control group (CG) and the hearing loss group (HLG) on background data. AES-S, Apathy Evaluation Scale – 
Self-rated; CESD-10, Center for Epidemiologic Studies Depression Scale – 10 item; Conroy, Conroy Boredom 
proneness; DJGLS, 6-item De Jong Gierveld Loneliness Scale; HADS-A, Hospital Anxiety and Depression Scale-
Anxiety subscale; HHIE-S, Hearing Handicap Inventory for the Elderly Screening Version; LSNS, Lubben Social 
Network Scale; NART, National Adult Reading Test; PSQI, Pittsburgh Sleep Quality Index; PSS-4, Perceived 
Stress Scale-4 item; PTA, Pure-tone average; SHARE, Survey of Health, Ageing and Retirement in Europe 
Frailty Instrument; WHO, World Health Organisation.
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ratio in working memory than to perceptual difficulties. This pattern has been observed previously only in asymp-
tomatic carriers of the E280A single presenilin-1 mutation which leads in 100% of cases to autosomic dominant 
familial AD9. In this study, Parra and colleagues9 also reported poorer (but not significantly poorer) performance 
for the asymptomatic carriers compared to controls on an identical complex figure copy task. AD and stroke 
studies indicate that performance on drawing tasks is modulated by several frontal and temporal-parietal cortex 
regions including the right temporal and parahippocampal gyri18–22 in which atrophy has been observed with 
ARHL23,24.
A meta-analysis of epidemiological studies reported that ARHL was associated with decline in multiple 
domains of cognition including working memory and visuospatial ability2. However, there is limited research 
into what initial changes may occur in neurocognitive function with ARHL prior to a stage where decline may be 
observed in multiple domains of cognition. The results of this study suggests that altered VSTMB may be a feature 
of such early changes in neurocognitive function with ARHL. Our findings are consistent with previous research. 
It is known that in ARHL the brain undergoes functional reorganization and that this might negatively impact on 
HLG M (SD) CG M (SD) p
Current sleepiness
Stanford Sleepiness Scale 1.72 (0.89) 1.89 (0.9) 0.48
Episodic memory
FCSRT immediate free recall 33.28 (7.19) 34.39 (4.35) 0.53
FCSRT immediate total recall 47.64 (1.41) 48 (0) 0.13
FCSRT delayed free recall 12.52 (2.74) 12.11 (2.06) 0.6
FCSRT delayed total recall 15.92 (0.4) 16 (0) 0.4
WMS-III spatial span forward 7.08 (2.04) 7 (1.82) 0.9
Composite z-score 0.004 (0.85) −0.01 (0.58) 0.97
Executive function
CAMDEX VR 3.68 (1.15) 3.83 (1.25) 0.68
SART commission errors 3.12 (2.37) 3.89 (2.97) 0.47
SART omission errors 6.24 (5.61) 10.33 (10.34) 0.25
SART total errors 9.36 (7.4) 14.22 (11.56) 0.18
Phon. fluency (MoCA) 15.04 (4.79) 14.22 (4.17) 0.56
WMS-III SS backward 6.44 (1.76) 6.67 (1.82) 0.68
WMS-III SS total 13.52 (3.33) 13.67 (3.2) 0.89
Composite z-score 0.06 (0.59) −0.08 (0.7) 0.47
Processing speed
CRT motor MRT (ms) 302.97 (76.65) 297.30 (56.19) 0.91
CRT cognitive MRT (ms) 485.57 (66.29) 501.85 (66.15) 0.36
CRT total MRT (ms) 788.46 (85.07) 797.43 (84.53) 0.74
SART MRT (ms) 334.13 (82.29) 319.14 (62.53) 0.6
Language
BNT 55.64 (3.6) 56.5 (2.33) 0.59
Semantic fluency (animals) 22.84 (5.45) 22.83 (6.36) >0.99
Composite z-score −0.06 (0.87) 0.08 (0.69) 0.59
Visuospatial ability
MCG complex figure copy 24.22 (4.38) 27.06 (4.5) 0.045
Global cognition
MoCA 25.96 (2.85) 26 (2.74) 0.96
MoCA adj. 17.72 (1.79) 17.72 (2.02) >0.99
Composite global z-score+ −0.04 (0.53) 0.06 (0.42) 0.51
Table 2. Neuropsychological data for the two groups of participants. Means (M) and standard deviation (SD) 
for the control group (CG) and the hearing loss group (HLG) on the neuropsychological data. +Composite 
global z-score calculated from the mean of the composite scores for episodic memory (except FCSRT total 
scores), executive functions (except SART and WMS-III spatial span total scores) and language, and from 
processing speed (CRT total MRT), and visuospatial ability. BNT, Boston Naming Test 60-item version; 
CAMDEX VR, Cambridge Mental Disorders of the Elderly Examination battery Visual Reasoning subtest; CRT, 
choice-reaction time test which included motor, cognitive and total mean reaction times (MRT) in milliseconds 
(ms); FCSRT, Free and Cued Selective Reminding Test with free and total (cued) recall scores; MCG, Medical 
College of Georgia Complex Figure copy test; MoCA, Montreal cognitive Assessment with an adjusted score 
(audiological items removed); SART, Sustained Attention to Response Task commission, omission and total 
error scores and mean reaction time (MRT) in milliseconds (ms); WMS-III, Wechsler Memory Scale-III spatial 
span forward, backward and total scores.
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the ability to retain information in memory (i.e. maladaptive plasticity)23,25–27. A small number of neuro-imaging 
studies have reported atrophy in neural regions that are important for memory with ARHL23,24,26,27.
Two studies that examined data from the Baltimore Longitudinal Study of Aging reported a faster decline 
in the temporal lobes in regions that are critical for memory23,26. One of these studies reported that ARHL was 
associated with accelerated atrophy (comparable to those developing mild cognitive impairment) in the para-
hippocampal gyrus23 which is part of the ventral stream and contributes to the encoding and maintenance of 
bound information in working memory28–30. The other study reported that poorer midlife hearing was associated 
with atrophy in the right hippocampus and in the entorhinal cortex26. Another recent study using data from the 
Alzheimer’s Disease Neuroimaging Initiative (ADNI) database also reported that ARHL was associated with 
elevated cerebrospinal fluid tau levels and atrophy of the hippocampus and entorhinal cortex27. The entorhinal 
cortex is affected in the early stages of AD31 but cortical thickness of this region has also been linked with memory 
scores independent of the level of β-amyloidosis and tauopathy32.
A limited number of studies have been conducted examining the link between neural changes with ARHL 
and changes in cognitive function in humans33–35. One such study reported a correlation of poorer function in 
several cognitive domains including episodic memory and visuoconstructive ability with atrophy in the cingu-
late cortex35, a neural region important for maintenance in working memory36,37. Support for a causal relation-
ship between ARHL and neurocognitive decline comes from several mouse studies which report brain atrophy, 
impaired neurogenesis (including in the hippocampus) and increased expression of phosphorylated tau following 
hearing loss along with impaired learning and memory38–42. If we consider that VSTMB relies on a network which 
involves regions known to be functionally disrupted in ARHL individuals and in prodromal AD7, then the selec-
tive VSTMB deficits observed in this study may be indexing such a negative functional reorganization which is 
thought to be a potential mechanism linking ARHL to dementia. Such a hypothesis will need investigation.
Multiple hypotheses exist as to how ARHL and dementia may be connected. There may be a common causal 
mechanism such as vascular determinants, a mechanistic pathway such as neural reorganization due to hearing 
loss or a mediating factor such as social isolation following ARHL6. Neuro-imaging evidence suggests that this 
functional reorganization may be driven by an impoverished auditory input or by the attentional load asso-
ciated with difficulties in perceiving speech following ARHL25,43. Findings from our exploratory analyses are 
consistent with this. Those in the HLG who performed poorly on the VSTMB task had greater hearing loss in the 
lower frequencies (crucial for speech) indicating further advancement in the ARHL pathophysiological process. 




Condition −0.060 −0.091 to −0.029 −3.86 <0.001
Group −0.018 −0.048 to 0.011 −1.26 0.22
Age 0.000 −0.003 to 0.002 −0.19 0.85
Sex −0.017 −0.047 to 0.014 −1.11 0.28
Education (years) 0.001 −0.003 to 0.006 0.55 0.59
β 95% CI t p
Condition 0.041 −0.060 to 0.142 0.82 0.42
Group 0.057 −0.021 to 0.135 1.48 0.15
Group*Condition −0.064 −0.125 to −0.003 −2.11 0.04
Age −0.0002 −0.003 to 0.002 −0.19 0.85
Sex −0.017 −0.047 to 0.014 −1.11 0.28
Education (years) 0.001 −0.003 to 0.006 0.55 0.59
ANCOVA analysis of difference on each VSTMB outcome
HLG CG Significance test
M (SD) Range M (SD) Range F p
Shape MRT (ms) 2153.96 (427.43) 1561–3514 2061.61 (319.21) 1507–2792 0.26 0.61
Shape Acc. 0.95 (0.05) 0.78–1 0.96 (0.04) 0.88–1 0.24 0.63
Shape A’ 0.97 (0.05) 0.77–1 0.98 (0.03) 0.88–1 0.74* 0.39
Bind MRT (ms) 2562.36 (550.03) 1832–4455 2330.11 (559.68) 1435–3475 0.78 0.38
Bind Acc. 0.86 (0.11) 0.62–1 0.93 (0.06) 0.78–1 4.92 0.03
Bind A’ 0.8 (0.23) 0.23–1 0.92 (0.08) 0.7–1 3.66 0.06
Table 3. VSTMB task outcomes for the two groups of participants. The visual short-term memory binding 
(VSTMB) task outcomes for the control group (CG) and the hearing loss group (HLG). Linear mixed models 
were used to examine the primary outcome of change in accuracy from shapes to binding conditions between 
groups. The ANCOVA models were used to assess all the outcomes of the VSTMB test as a secondary analysis. 
Age, sex and years of education were included in linear mixed and ANCOVA models as covariates. Mean 
Reaction Time (MRT) for shapes transformed to inverse of square root to account for non-normality. Binding A’ 
data transformed to a squared scale. *Assessed using rank analysis of covariance.
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Additionally, they had lower phonemic fluency scores, possibly reflecting the decline in phonological abilities 
previously observed in ARHL5.
Higher cognitive load in auditory working memory when processing speech may draw resources from ven-
tral stream regions44 which maintain feature binding45. Also, altered visual attention to assist speech perception 
following early stage ARHL may drive cross-modal reorganization along the ventral visual stream in temporal 
regions associated with auditory processing25,46. Interestingly, mild AD patients present altered visual attention 
when processing bound (but not unbound) features, possibly reflecting inefficient cortical mechanisms respon-
sible for encoding bindings47.
Alternatively, a common pathophysiological mechanism may affect both the inner ear and neural regions 
sub-serving feature binding. While the primary risk factor for both ARHL and AD dementia is age48, the VSTMB 
task has been demonstrated to be insensitive to ageing49. Additionally, pathophysiologic features of AD have 
been observed in central auditory neural regions but not in the peripheral auditory structures50. Genetic risk 
factors may account for such an association. For example, ApoE e4 (apolipoprotein E-epsilon4) is strongly linked 
in isoform-dependent manner with sporadic AD51,52 and ARHL53,54, possibly through changes in cholesterol 
homeostasis55 or hypercholesterolemia in the main vasculature and associated atherosclerosis56,57. Other possible 
common mechanisms include the metabotropic glutamate receptor gene which is linked to both ARHL and AD 
via the glutamatergic pathway or mitochondrial dysfunction via the SIRT3 pathway48.
Limitations. The primary limitation of our study is small sample sizes and a small number of VSTMB trials 
which may have resulted in an underestimation of the difference between groups. Additionally, while we found 
a weaker capacity to form visual bindings with ARHL, we cannot deduce from these findings how ARHL and 
impaired VSTMB are connected. Our findings provide some support for the hypothesis that ARHL mechanisti-
cally affects cognitive function based on prior literature as reported here. Limited research has been conducted on 
changes in cognitive processing with ARHL prior to decline in performance on more general cognitive tests such 
as the MoCA as observed in epidemiological studies. Further research is warranted to examine if altered visual 
short-term memory processing is a feature of early cognitive decline following ARHL. Neuro-imaging studies 
examining the neural correlates of binding in an ARHL sample compared to controls and AD samples would be 
informative. Any differences or similarities in neural correlates of binding across ARHL and AD groups matched 
in behavioral performance would help to elucidate the underlying pathophysiological processes linking ARHL 
with dementia. Genetic markers for both ARHL and AD could also be assessed. Furthermore, longitudinal stud-
ies are required to assess the validity of impaired VSTMB in predicting future risk of dementia with ARHL.
The VSTMB test is purely visual making it appropriate for use with ARHL patients. In our sample, maintained 
executive resources could not compensate for weaker binding capacity. Also, the VSTMB test does not have any 
linguistic components meaning that it can be used globally and in developing countries which are preferentially 
affected by both ARHL and dementia. It is insensitive to normal cognitive ageing, education and cultural back-
ground45. Furthermore, VSTMB is not impaired in other age-related clinical conditions including depression, 
vascular dementia, dementia with Parkinson’s disease, dementia with Lewy bodies and frontal lobe dementia45.
Clinical trials aimed at maintaining or rehabilitating cognitive function in ARHL could include VSTMB as a 
target for therapeutic success or as a preclinical marker to identify potential participants. Hearing aids can reduce 
attentional costs, particularly when equipped with algorithms to improve speech-in-noise perception5. Also, ben-
efits for visuospatial working memory have been noted58. However, the majority of the HLG reported wearing 
hearing aids suggesting that additional interventions may be required.
Conclusions
In conclusion, we found a decline in VSTMB with hearing loss which has only previously been reported in AD 
samples. To the best of our knowledge this is the first study to link ARHL with a potential preclinical cognitive test 
for AD. Further research is warranted to examine the mechanism underpinning the relationship of ARHL with 
VSTMB and examine it as a potential biomarker for future dementia.
Data Availability
Following publication, anonymized data will be shared by request from any qualified investigator.
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